LncRNA DANCR functions as a competing endogenous RNA to regulate RAB1A expression by sponging miR-634 in glioma

Abstract

Long noncoding RNA (lncRNA) differentiation antagonizing nonprotein coding RNA (DANCR) plays important regulatory roles in many solid tumors. However, the effect of DANCR in glioma progression and underlying molecular mechanisms were not entirely explored. In the present study, we determined the expression of DANCR in glioma tissues and cell lines using qRT-PCR and further defined the biological functions. Furthermore, we used luciferase reporter assay, Western blot, and RNA immunoprecipitation (RIP) to explore the underlying mechanism. Our results showed that DANCR was significantly up-regulated in glioma tissues and cell lines (U251, U118, LN229, and U87MG). High DANCR expression was correlated with advanced tumor grade. Inhibition of DANCR suppressed the glioma cells proliferation and induced cells arrested in the G0/G1 phase. In addition, we verified that DANCR could directly interact with miR-634 in glioma cells and this interaction resulted in the inhibition of downstream of RAB1A expression. The present study demonstrated that DANCR/miR-634/RAB1A axis plays crucial roles in the progression of glioma, and DANCR might potentially serve as a therapeutic target for the treatment of glioma patients.

Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR‐874‐3P/ATG16L1 axis

“…Indeed, as shown in Figure 4B, DANCR with wild-type 3'UTR sequence (wt) interacted with miR-874-3P, and DANCR with mutations (mut) in miR-874-3P targeting sites had no similar effect. As positive controls, miR-634 and miR-496, two miRNAs previously shown to bind with DANCR Xu et al, 2018), were simultaneously found present in pull-down products, confirming the validity of this assay. Moreover, the specific interaction between DANCR and miR-874-3P was also supported by the evidence obtained from anti-Ago2 RNA immunoprecipitation (RIP) assay (Figure 4C).…”

“…One critical mechanism by which lncRNAs regulate gene expression is acting as ceRNAs to sponge targeted miRNAs (Salmena et al, 2011). This is also true for DANCR, not only because several miRNAs have been identified as direct targets of DANCR, but also the function of DANCR is prominently mediated through downregulating the expression of these miRNAs, as reported by recent studies Lu et al, 2018;Wang et al, 2018a;Wang et al, 2018b;Xu et al, 2018;Yang et al, 2018), to name a few. Combining predictive methods and some biochemical experiments, we demonstrate that miR-874-3P is a new binding target of DANCR and that by suppressing the inhibitory effect of miR-874-3P on ATG16L1 expression via interacting and decreasing miR-874-3P level, DANCR possesses an ability to upregulate ATG16L1 expression.…”

Long noncoding RNA DANCR knockdown inhibits proliferation, migration and invasion of glioma by regulating miR-135a-5p/BMI1

“…Mounting evidence suggested that lncRNAs could function as miRNA sponges or decoys to regulate the expressions of miRNAs targets genes in different types of cancer, including glioma [26,27]. Some literatures have revealed several target miRNAs of DANCR in glioma.…”

“…Some literatures have revealed several target miRNAs of DANCR in glioma. For instance, DANCR regulated RAB1A expression in glioma by functioning as a ceRNA of miR-634 [27]. In addition, DANCR has been reported to promote glioma malignancy by miR-33a-5p [28].…”

<p>Meta-analysis of the prognostic value of <em>lncRNA DANCR</em> for cancer patients in China</p>

“…[12][13][14] Moreover, lncRNA DANCR is also suggested in some studies to be correlated with different tumor biological parameters, such as tumor growth, metastasis, and progression. [15][16][17] Metastasis and prognosis may be affected by lncRNA DANCR; nonetheless, a majority of existing studies are limited by their small sample sizes and discrete outcomes. As a consequence, an updated meta-analysis was performed in this study to determine the prognostic value of lncRNA DANCR in cancer patients.…”